FDA Inspection
Inopak LtdInopak Ltd – FDA Inspection, Mar 24, 2017
Record Details
This FDA Inspection record concerns Inopak Ltd, with an inspection on March 24, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 61aa82b7-8d34-4508-ae28-371152013f7a
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1010061
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
8- 21 CFR 211.110(a)Control procedures to monitor and validate performance
- 21 CFR 211.25(a)GMP Training Frequency
- 21 CFR 211.165(e)Test methods
- 21 CFR 211.84(d)(1)Identity Testing of Each Component
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.22(a)Lack of quality control unit
- 21 CFR 211.166(a)Lack of written stability program
- FDCA 601(c)Insanitary conditions; contaminated with filth
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Inopak Ltd
6| Date | Classification | Office | Project area |
|---|---|---|---|
| August 3, 2023 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 18, 2021 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 20, 2018 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 11, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 11, 2012 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Inopak Ltd
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.